Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma

Johannes M Waldschmidt; Noori Sotudeh; Sankalp Arora; Tushara Vijaykumar; Praveen Anand; Hannah Stuart; Julia Frede; Tim Campbell; Shari M Kaiser; Xirong Zheng; Nikhil C Munshi; Kenneth C Anderson; Hermann Einsele; Andrew J Yee; Birgit Knoechel; Jens G Lohr; Noopur S Raje

doi:10.1182/bloodadvances.2024015285

Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma

Blood Adv. 2025 Mar 11;9(5):1132-1136. doi: 10.1182/bloodadvances.2024015285.

Authors

Johannes M Waldschmidt^{1

2

3

4}, Noori Sotudeh^{1

2

3}, Sankalp Arora^{5

6}, Tushara Vijaykumar^{1

2}, Praveen Anand^{1

2

3}, Hannah Stuart^{1

2

3}, Julia Frede^{1

2

3}, Tim Campbell⁷, Shari M Kaiser⁷, Xirong Zheng⁷, Nikhil C Munshi^{1

2}, Kenneth C Anderson^{1

2}, Hermann Einsele⁴, Andrew J Yee⁵, Birgit Knoechel^{2

3

8}, Jens G Lohr^{1

2

3}, Noopur S Raje^{2

5}

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
² Harvard Medical School, Boston, MA.
³ Broad Institute of MIT and Harvard, Cambridge, MA.
⁴ Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.
⁵ Department of Hematology/Oncology, Center for Multiple Myeloma, Massachussetts General Hospital, Boston, MA.
⁶ Department of Hematology, MD Anderson Cancer Center, Houston, TX.
⁷ Bristol Myers Squibb, Princeton, NJ.
⁸ Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.

No abstract available

Grants and funding